Form 4: Camp4 Therapeutics Director Holtzman Converts Preferred Stock to Common Stock Following IPO

Director Steven H. Holtzman converted Series A Prime Preferred Stock to Common Stock in Camp4 Therapeutics following the company's initial public offering.

Summary

• On October 15, 2024, Steven H. Holtzman, a director of Camp4 Therapeutics Corp, converted 100,014 shares of Series A Prime Convertible Preferred Stock into 8,917 shares of Common Stock.
• The conversion occurred automatically upon the closing of Camp4 Therapeutics' initial public offering (IPO).
• The conversion ratio was 11.2158-for-one, meaning each share of preferred stock converted into 11.2158 shares of common stock.
• Following the transaction, Holtzman directly owns 108,946 shares of Common Stock.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to an expected conversion of stock following an IPO. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are standard practice following significant transactions, such as an IPO, that affect the holdings of company insiders. This filing indicates the conversion of preferred stock to common stock, which is a typical event post-IPO.

Stakeholder Impact

• The conversion of preferred stock to common stock may have a minor dilutive effect on existing common shareholders.

Key Dates